Amylyx Pharmaceuticals, Inc. (AMLX): Cash & Equivalents
$226.65M
As of 2025-12-31
$49.33M
As of 2026-06-30
+53.6%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $226.65M | +192.9% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $77.39M | -54.5% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $170.20M | +172.2% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $62.53M | +24.6% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $50.19M | n/a | 2023-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $226.65M | +192.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare AMLX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗